176 related articles for article (PubMed ID: 29210587)
1. Organocatalytic Asymmetric Synthesis of Spiro-oxindole Piperidine Derivatives That Reduce Cancer Cell Proliferation by Inhibiting MDM2-p53 Interaction.
Yang MC; Peng C; Huang H; Yang L; He XH; Huang W; Cui HL; He G; Han B
Org Lett; 2017 Dec; 19(24):6752-6755. PubMed ID: 29210587
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of spiro-tetrahydrothiopyran-oxindoles by Michael-aldol cascade reactions: discovery of potential P53-MDM2 inhibitors with good antitumor activity.
Wang S; Chen S; Guo Z; He S; Zhang F; Liu X; Chen W; Zhang S; Sheng C
Org Biomol Chem; 2018 Jan; 16(4):625-634. PubMed ID: 29302672
[TBL] [Abstract][Full Text] [Related]
3. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
[TBL] [Abstract][Full Text] [Related]
4. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
[TBL] [Abstract][Full Text] [Related]
5. Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators.
Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A
Bioorg Chem; 2021 Dec; 117():105427. PubMed ID: 34794098
[TBL] [Abstract][Full Text] [Related]
6. Meeting Organocatalysis with Drug Discovery: Asymmetric Synthesis of 3,3'-Spirooxindoles Fused with Tetrahydrothiopyrans as Novel p53-MDM2 Inhibitors.
Wang S; Jiang Y; Wu S; Dong G; Miao Z; Zhang W; Sheng C
Org Lett; 2016 Mar; 18(5):1028-31. PubMed ID: 26883465
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors.
Ji C; Wang S; Chen S; He S; Jiang Y; Miao Z; Li J; Sheng C
Bioorg Med Chem; 2017 Oct; 25(20):5268-5277. PubMed ID: 28797774
[TBL] [Abstract][Full Text] [Related]
8. One-pot synthesis of spiro(indoline-3,4'-pyrazolo[3,4-b]pyridine)-5'-carbonitriles as p53-MDM2 interaction inhibitors.
Ibrahim HS; Eldehna WM; Fallacara AL; Ahmed ER; Ghabbour HA; Elaasser MM; Botta M; Abou-Seri SM; Abdel-Aziz HA
Future Med Chem; 2018 Dec; 10(24):2771-2789. PubMed ID: 30526032
[TBL] [Abstract][Full Text] [Related]
9. Organocatalytic cascade reaction for the asymmetric synthesis of novel chroman-fused spirooxindoles that potently inhibit cancer cell proliferation.
Zhou R; Wu Q; Guo M; Huang W; He X; Yang L; Peng F; He G; Han B
Chem Commun (Camb); 2015 Aug; 51(66):13113-6. PubMed ID: 26186061
[TBL] [Abstract][Full Text] [Related]
10. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.
Shangary S; Ding K; Qiu S; Nikolovska-Coleska Z; Bauer JA; Liu M; Wang G; Lu Y; McEachern D; Bernard D; Bradford CR; Carey TE; Wang S
Mol Cancer Ther; 2008 Jun; 7(6):1533-42. PubMed ID: 18566224
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of p53-Murine Double Minute 2 (MDM2) Interactions with 3,3'-Spirocyclopentene Oxindole Derivatives.
Gicquel M; Gomez C; Garcia Alvarez MC; Pamlard O; Guérineau V; Jacquet E; Bignon J; Voituriez A; Marinetti A
J Med Chem; 2018 Oct; 61(20):9386-9392. PubMed ID: 30221935
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of nitroisoxazole-containing spiro[pyrrolidin-oxindole] derivatives as novel glutathione peroxidase 4/mouse double minute 2 dual inhibitors that inhibit breast adenocarcinoma cell proliferation.
Liu SJ; Zhao Q; Peng C; Mao Q; Wu F; Zhang FH; Feng QS; He G; Han B
Eur J Med Chem; 2021 May; 217():113359. PubMed ID: 33725632
[TBL] [Abstract][Full Text] [Related]
13. Computational analysis of spiro-oxindole inhibitors of the MDM2-p53 interaction: insights and selection of novel inhibitors.
Huang W; Cai L; Chen C; Xie X; Zhao Q; Zhao X; Zhou HY; Han B; Peng C
J Biomol Struct Dyn; 2016; 34(2):341-51. PubMed ID: 25808617
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
[TBL] [Abstract][Full Text] [Related]
15. Spiro[pyrrolidine-3, 3´-oxindole] as potent anti-breast cancer compounds: Their design, synthesis, biological evaluation and cellular target identification.
Hati S; Tripathy S; Dutta PK; Agarwal R; Srinivasan R; Singh A; Singh S; Sen S
Sci Rep; 2016 Aug; 6():32213. PubMed ID: 27573798
[TBL] [Abstract][Full Text] [Related]
16. Core-Scaffold-Inspired Asymmetric Synthesis of Polysubstituted Chiral Hexahydropyridazines that Potently Inhibit Breast Cancer Cell Proliferation by Inducing Apoptosis.
Leng HJ; Peng F; Zingales S; Huang W; Wang B; Zhao Q; Zhou R; He G; Peng C; Han B
Chemistry; 2015 Dec; 21(50):18100-8. PubMed ID: 26498568
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
Ding K; Lu Y; Nikolovska-Coleska Z; Wang G; Qiu S; Shangary S; Gao W; Qin D; Stuckey J; Krajewski K; Roller PP; Wang S
J Med Chem; 2006 Jun; 49(12):3432-5. PubMed ID: 16759082
[TBL] [Abstract][Full Text] [Related]
18. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of new thiazolo-pyrrolidine-(spirooxindole) tethered to 3-acylindole as anticancer agents.
Islam MS; Ghawas HM; El-Senduny FF; Al-Majid AM; Elshaier YAMM; Badria FA; Barakat A
Bioorg Chem; 2019 Feb; 82():423-430. PubMed ID: 30508794
[TBL] [Abstract][Full Text] [Related]
20. Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.
Chen H; Luo D; Zhang L; Lin X; Luo Q; Yi H; Wang J; Yan X; Li B; Chen Y; Liu X; Zhang H; Liu S; Qiu M; Yang D; Jiang N
Oncotarget; 2017 Jun; 8(26):43008-43022. PubMed ID: 28498808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
